Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis
ConclusionMyosteatosis is highly prevalent in patients with cirrhosis, particularly in those with NAFLD-associated cirrhosis. Myosteatosis is associated with hepatic encephalopathy, while it seems to have a negative impact on the outcome. (Source: Hepatology International)
Source: Hepatology International - February 8, 2024 Category: Infectious Diseases Source Type: research
Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues
(Source: Hepatology International)
Source: Hepatology International - February 8, 2024 Category: Infectious Diseases Source Type: research
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes
ConclusionsLiver fibrosis, as estimated by FIB-4, may serve as a more reliable prognostic indicator for individuals living with diabetes than hepatic steatosis. Individuals living with diabetes with FIB-4 ≥ 1.3 without moderate–severe steatosis had a significantly increased all-cause mortality risk. These findings highlight the importance of identifying and monitoring those individuals, as they may benefit from further evaluation and risk stratification.Graphical abstract (Source: Hepatology International)
Source: Hepatology International - January 22, 2024 Category: Infectious Diseases Source Type: research
Correction to: Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines
(Source: Hepatology International)
Source: Hepatology International - January 22, 2024 Category: Infectious Diseases Source Type: research
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
ConclusionsReal-world data from Taiwan confirmed that simplified HCV treatment for eligible patients with pan-genotypic regimens is effective and well tolerated. The TACR algorithm, developed based on this study ’s results, can further identify patients who can be safely managed by non-specialist care.Graphical Abstract (Source: Hepatology International)
Source: Hepatology International - January 21, 2024 Category: Infectious Diseases Source Type: research
Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease
ConclusionsIn this large population-based study, cryptogenic SLD, the excluded group, occupy only 3.5% in NAFLD patients. It has lower liver and atherosclerotic risks than MASLD, supporting its exclusion from NAFLD and justifying the rationale for the new disease name and diagnostic criteria of MASLD. (Source: Hepatology International)
Source: Hepatology International - January 16, 2024 Category: Infectious Diseases Source Type: research
Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma
ConclusionCompared to lenvatinib, atezolizumab-bevacizumab was associated with a favorable organ-specific response regardless of the site of the tumor lesions. Unlike anti-PD-1 monotherapy, atezolizumab-bevacizumab had a comparable organ-specific response between intrahepatic and extrahepatic lesions, especially for those with viral etiology HCCs. (Source: Hepatology International)
Source: Hepatology International - January 12, 2024 Category: Infectious Diseases Source Type: research
The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver disease
ConclusionsANXA2 is a pathological predictor and promising therapeutic target for NAFLD. ANXA2 plays a crucial role in linking inflammation to hepatic metabolic disorder and injury, mainly through the blockage of AMPK/mTOR-mediated lipophagy.Graphic abstract (Source: Hepatology International)
Source: Hepatology International - January 6, 2024 Category: Infectious Diseases Source Type: research
FXR overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in alcoholic liver disease
ConclusionsFXR attenuated lipid metabolism disorders and lipid degeneration in alcohol-caused liver injury and alleviated oxidative stress and inflammation by inhibiting AIM2 inflammasome activation.Graphical abstract (Source: Hepatology International)
Source: Hepatology International - January 6, 2024 Category: Infectious Diseases Source Type: research
Bile acids induce liver fibrosis through the NLRP3 inflammasome pathway and the mechanism of FXR inhibition of NLRP3 activation
Conclusion(1) Primary conjugated bile acids increased in patients with liver fibrosis; (2) GCDCA induce hepatic fibrosis via the NLRP3 inflammasome pathway; (3) FXR inhibits NLRP3 activity by restraining its phosphorylation; (4) knockdown or knockout of NLRP3 may relieve the onset of hepatic fibrosis. (Source: Hepatology International)
Source: Hepatology International - January 3, 2024 Category: Infectious Diseases Source Type: research
Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis
ConclusionsInterferon may significantly reduce recurrence and improve DFS of patients with HBV-related HCC after curative surgery, and finally improve the OS. However, the efficacy advantage may gradually weaken as time goes on. The clinical application of interferon combined with NAs recommended in this meta-analysis is needed to be further studied. (Source: Hepatology International)
Source: Hepatology International - January 2, 2024 Category: Infectious Diseases Source Type: research
Integrating single-cell and bulk RNA sequencing reveals CK19 + cancer stem cells and their specific SPP1 + tumor-associated macrophage niche in HBV-related hepatocellular carcinoma
ConclusionsThis study revealed the heterogeneity and stemness characteristics of CK19 + CSCs and specific immunosuppressive TAM_SPP1 in CK19 + HCC. The VEGFA signal can activate TAM_SPP1-derived MMP9 to promote the invasion and metastasis of CK19 + HCC tumors. This might provide novel insights into the clinical treatment of HCC patients.Graphical abstractLay summary: Cytokeratin 19-positive hepatocellular carcinoma is a highly aggressive malignancy with poor therapeutic progress. Understanding the characteristics of CK19 + CSCs and their immune microenvironment better might facilitate the development of effect...
Source: Hepatology International - December 30, 2023 Category: Infectious Diseases Source Type: research
Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors ’ reply
(Source: Hepatology International)
Source: Hepatology International - December 23, 2023 Category: Infectious Diseases Source Type: research
Correction to: Targeting ferroptosis in hepatocellular carcinoma
(Source: Hepatology International)
Source: Hepatology International - December 21, 2023 Category: Infectious Diseases Source Type: research
Breaking new ground: MASLD vs. MAFLD —which holds the key for risk stratification?
ConclusionsAlthough MASLD has a higher capture of lean patients compared to MAFLD, patients with MAFLD and MASLD have a worse metabolic profile than those with only MASLD. Our results provide evidence that MAFLD better identifies patients likely to have a higher risk of liver fibrosis and of disease progression.Graphical abstract (Source: Hepatology International)
Source: Hepatology International - December 21, 2023 Category: Infectious Diseases Source Type: research
